Blood Levels of Glutamate and Glutamine in Recent Onset and Chronic Schizophrenia

Converging evidence indicates that dysfunctions in glutamatergic neurotransmission and in the glutamate-glutamine cycle play a role in the pathophysiology of schizophrenia. Here, we investigated glutamate and glutamine levels in the blood of patients with recent onset schizophrenia or chronic schizo...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in psychiatry Vol. 9; p. 713
Main Authors Madeira, Caroline, Alheira, Flavio V, Calcia, Marilia A, Silva, Thuany C S, Tannos, Filippe M, Vargas-Lopes, Charles, Fisher, Melissa, Goldenstein, Nelson, Brasil, Marco Antonio, Vinogradov, Sophia, Ferreira, Sergio T, Panizzutti, Rogerio
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 19.12.2018
Subjects
blood
chronic schizophrenia
glutamate
glutamine
Psychiatry
recent onset schizophrenia
chronic schizophrenia
glutamine
recent onset schizophrenia
blood
glutamate
Online AccessGet full text

Cover

More Information
Summary:Converging evidence indicates that dysfunctions in glutamatergic neurotransmission and in the glutamate-glutamine cycle play a role in the pathophysiology of schizophrenia. Here, we investigated glutamate and glutamine levels in the blood of patients with recent onset schizophrenia or chronic schizophrenia compared to healthy controls. Compared with healthy controls, patients with recent onset schizophrenia showed increased glutamine/glutamate ratio, while patients with chronic schizophrenia showed decreased glutamine/glutamate ratio. Results indicate that circulating glutamate and glutamine levels exhibit a dual behavior in schizophrenia, with an increase of glutamine/glutamate ratio at the onset of schizophrenia followed by a decrease with progression of the disorder. Further studies are warranted to elucidate the mechanisms and consequences of changes in circulating glutamate and glutamine in schizophrenia.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Svetlana Ivanova, Mental Health Research Institute, Tomsk NRMC, Russia; Stefania Schiavone, University of Foggia, Italy
Edited by: Hsien-Yuan Lane, China Medical University, Taiwan
This article was submitted to Molecular Psychiatry, a section of the journal Frontiers in Psychiatry
ISSN:1664-0640
1664-0640
DOI:10.3389/fpsyt.2018.00713